Immunoprotein is an immunologically active protein, which provides immunity against pathogenic organisms or substances. These proteins form the integrated body system of tissues, organs, cells, or cell products that neutralize antigens. They enable the diagnosis of various diseases, such as cardiovascular, oncology, infectious diseases, and others, as they display an abnormal increase in their concentration when in a diseased state. Increase in incidence & prevalence of chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services drive the market growth. However, complex regulatory framework for immunoprotein diagnostic testing limits the growth. The global immunoprotein diagnostic testing market is accounted for $16,485 million in 2016, and is estimated to reach $27,290 million by 2022, growing at a CAGR of 7.4% during the analysis period (2017-2023).

The market is segmented on the basis of type, application, technology, and geography. By type, the market is categorized into C-reactive protein diagnostic test, complement system protein diagnostic test, prealbumin diagnostic test, haptoglobin diagnostic test, immunoglobulin diagnostic test, free light chain diagnostic test, and others. Applications covered in the study include autoimmune disease testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. Based on technology, it is classified into radioimmunoassay, immunoturbidity assay, chemiluminescence assay, immunoprotein electrophoresis, enzyme-based immunoassay, immunofluorescence assay, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS:

The study provides an in-depth analysis of the global immunoprotein diagnostic testing market with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report provides a quantitative analysis for the period of 2016-2023, which enables stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand the various products of the market.
Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

KEY MARKET SEGMENT:

By Technology

Radioimmunoassay
Immunoturbidity Assay
Chemiluminescence Assay
Immunoprotein Electrophoresis
Enzyme-Based Immunoassay
Immunofluorescence Assay
Others

By Type

C-reactive Protein Diagnostic Test
Complement System Protein Diagnostic Test
Prealbumin Diagnostic Test
Haptoglobin Diagnostic Test
Immunoglobulin Diagnostic Test
Free Light Chain Diagnostic Test
Others

By Application

Autoimmune Testing
Infectious Disease Testing
Allergy Testing
Endocrine Testing
Oncology Testing
Toxicology Testing
Others

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Others
Asia Pacific
Japan
China
India
Others
LAMEA
Latin America
Middle East
Africa

List of players profiled in the report

Abbott Laboratories
Abcam PLC
Bio-Rad Laboratories
Danaher Corporation
Diasorin
Enzo Life Sciences
Ortho Clinical Diagnostics
Roche Diagnostics
Siemens Healthcare
Thermo Fisher Scientific

List of other players (These companies are not profiled in the report and same can be done on demand)

Affymetrix
Alere
bioMerieux
ORGENTEC Diagnostika
Sekisui Diagnostics
IBL International
ImmunoDX
Quidel Corporation
Trinity Biotech